BioInvent International AB

About BioInvent International AB

BioInvent is a clinical-stage company focused on discovering and developing antibodies for cancer therapy. Based on extensive knowledge in immunology, cancer biology, and antibody biology, the company aims to improve cancer treatment and create value for patients, families, shareholders, and other stakeholders through innovative immuno-oncology drug candidates.

Products & Services

Clinical Programs:BioInvent has multiple ongoing clinical programs targeting cancer, including BI-1808 for T-cell lymphoma and solid tumors, BI-1206 for non-Hodgkin lymphoma (NHL) and solid tumors, and BT-001 for solid tumors.

F.I.R.S.T™ Platform:A unique development tool that uses patient material to identify clinically relevant targets and matching antibodies throughout the development process.

n-CoDeR® Antibody Library:A proprietary library containing antibodies that bind specifically and strongly to their targets, supporting the development of innovative therapies.

BioInvent Manufacturing:A contract manufacturing business unit with a proven track record since 1988, producing drug substances for clinical trials globally using single-use technology.

Specialties

Immuno-oncology Antibody development Cancer therapy Immunology Cancer biology Antibody biology Contract manufacturing

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Equity Investment T: - FT: Equity Investment	A: 3000000 MR: - FA: 3 million FAN: 3000000	D: 2023-01-17 FD: 2023-01-17	1 investors

Equity Investment Latest

2023-01-17

$3.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Mona Welschof

VP Clinical Development

L

Linda Mårtensson

Principal Scientist at BioInvent

B

Björn Frendéus

Chief Scientific Officer

S

Sylvie Ryckebusch

Head of Business Development

C

Cecilia Hofvander

VP Investor Relations

N

Natalie Berner

Member of R&D Committee and the Audit Committee

View 22 more team members with Pro

Unlock Full Team Directory

Recent News